Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis

To assess the safety, efficacy, and prognostic impact of clinical factors associated with lenvatinib treatment in highly advanced hepatocellular carcinoma (HCC) with tumor thrombus in the main portal vein trunk (VP4) or tumor with more than 50% liver occupation (tm50%LO).

[1]  A. Saga,et al.  Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  N. Sugiura,et al.  Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma , 2020, Liver Cancer.

[3]  Y. Hiasa,et al.  Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[4]  R. Lencioni,et al.  mRECIST for HCC: Performance and novel refinements. , 2020, Journal of hepatology.

[5]  Y. N. Park,et al.  Gross type of hepatocellular carcinoma reflects the tumor hypoxia, fibrosis, and stemness-related marker expression , 2020, Hepatology International.

[6]  M. Kudo,et al.  Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study , 2019, Cancers.

[7]  M. Kudo,et al.  Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis , 2019, Cancer medicine.

[8]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[9]  S. Kakar,et al.  Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR) , 2018, Histopathology.

[10]  A. Gasbarrini,et al.  Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice , 2018, Hepatology.

[11]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[12]  K. Rau,et al.  The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis , 2018, Investigational New Drugs.

[13]  M. Honda,et al.  Post‐progression survival and progression‐free survival in patients with advanced hepatocellular carcinoma treated by sorafenib , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  O. Yokosuka,et al.  Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib , 2016, Investigational New Drugs.

[15]  H. Ueno,et al.  Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma , 2015, Clinical Cancer Research.

[16]  Y. Imai,et al.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.

[17]  Y. Inaba,et al.  Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. , 2012, Journal of vascular and interventional radiology : JVIR.

[18]  L. Roberts,et al.  Epidemiology and management of hepatocellular carcinoma. , 2010, Infectious disease clinics of North America.

[19]  M. Omata,et al.  Combination therapy of intraarterial 5‐fluorouracil and systemic interferon‐alpha for advanced hepatocellular carcinoma with portal venous invasion , 2006, Cancer.

[20]  Vincenzo Savarino,et al.  Liver enzyme alteration: a guide for clinicians , 2005, Canadian Medical Association Journal.

[21]  Noriyuki Moriyama,et al.  Pathology of small hepatocellular carcinoma. A proposal for a new gross classification , 1987, Cancer.

[22]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .